Can we predict who will get dangerous side effects from a common brain cancer drug?
NCT ID NCT06546631
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at why some people with brain tumors (gliomas) develop low blood cell counts from the drug temozolomide, while others don't. Researchers will analyze genes, gut bacteria, and other factors in 55 patients to find clues. The goal is to help doctors predict and prevent this side effect in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide
What this could lead to
If successful, this could help doctors predict which patients are at higher risk of severe blood side effects from temozolomide, allowing them to take steps to reduce that risk.
What could go wrong
This is a small, early-stage observational study (55 participants) that aims to identify predictors, not test a new treatment. It may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cork University Hospital
RECRUITINGCork, Ireland